[HTML][HTML] Endocrine Adverse Events in Cancer Immunotherapy: From Mechanisms to Clinical Practice
O Aseyev, E Monaghan, Y Sun, H Shortreed, A Bishop - 2024 - intechopen.com
Immunotherapy-induced endocrinopathies remain an adverse risk factor for patients
undergoing PD-1/PD-L1 and CTLA-4 target immunotherapy treatment. Immunotherapy …
undergoing PD-1/PD-L1 and CTLA-4 target immunotherapy treatment. Immunotherapy …